On January 11, as the global healthcare industry gathered in San Francisco, the BIOSeedin Winter Innovation Partnering Summit successfully convened ahead of J.P. Morgan 2026. ACROBiosystems, as a key strategic partner, joined hands with multiple enterprises to participate in the event.

Hosted by bioSeedin and centered on the theme "Global Matching of Innovative Assets," the summit brought together multinational pharmaceuticals, investors, and emerging biotech companies to explore licensing opportunities and globalization strategies for innovative therapeutics. Over 500 delegates from more than ten countries and regions engaged in vibrant discussions, fostering extensive collaborative intentions. The event was also sponsored by Lilly, Roche, and Fangda Partners.

Committed to being a cornerstone of the global biopharmaceutical and healthcare industries by providing innovative products and business models, ACROBiosystems, against the backdrop of a new era defined by "capital + collaboration" in global medical innovation, embraced the brand proposition of "Connecting the world, your partner from discovery to the clinic." Through this summit, ACROBiosystems aimed to link resources, facilitate strategic partnerships, and empower global innovation.

In parallel with this vision, ACROBiosystems is committed to delivering reliable quality and considerate service.

ACROBiosystems set up a dedicated networking lounge at the summit, conducting in-depth dialogues with global pharmaceutical and biotech pioneers. Discussions focused on the global expansion pathway for locally-developed innovative drugs, addressing critical topics such as license-in/out cooperation, global clinical development, and market access, resulting in efficient and practical resource alignment for mutual value creation.

Industry Spotlight: Global Strategies and Local Innovations

Oncology Session: Panelists highlighted China's unique advantages in clinical speed, platform iteration, and portfolio strategy, predicting globally competitive innovations in ADC, TCE, and novel cell/gene therapies in the coming years.

Cardio-Renal-Metabolic Session: Experts emphasized de-risking clinical trials and recognized small biotech as the core driver of innovation, with MNCs leveraging distinct advantages in the cardiovascular market.

Autoimmune Session: Discussions centered on betting on FIC targets, with insights on smarter deal structures, regional stratification, and global coordination to accelerate value delivery.

The sessions featured senior leaders from leading global pharmaceutical companies, investment firms, and biotech organizations as moderators and panelists, including representatives from Pfizer, Roche, AbbVie, Daiichi-Sankyo, Takeda, bioSeedin, Bayer, Hengrui Pharma, RA Capital Management, Pacific Bridge NY, Hansoh Pharma, GSK, Boehringer Ingelheim, PIVOTAL BIOVENTURE PARTNERS, and Fangda Partners.

Companies including Adagene, EpimAb Biotherapeutics, Excalipoint Therapeutics, Convalife Pharmaceuticals, Innovative Cellular Therapeutics, Huaota Biopharmaceutical, Leads Biolabs, Youcare Pharmaceutical, Sciwind Biosciences, HighTide Therapeutics, Sirius Therapeutics, Alphamab, ImmuneOnco Biopharmaceuticals, Genrix Biopharmaceutical, Mabwell Bioscience, VelaVigo Bio, and Degron Therapeutics presented pipelines covering antibodies, bispecifics, TCE, ADC, molecular glues, the neuro-metabolic field, and more, drawing keen interest from attendees.